Selenium Supplementation in the Treatment of Hashimoto's Thyroiditis: A Systematic Review and a Meta-analysis

AbstractBackgroundSelenium forms a significant component of seleno-proteins in the body. Seleno-methionine is integrated into proteins instead of methionine and acts as a storage pool. In proteins, the active form of Selenium is seleno-cysteine.in this review we aim to prevail the results of selenium effect on thyroid status in recent clinical trials. The systemic review aims to find out the correlation between supplementation of Selenium and anti-TPO antibodies and T4 levels in Hashimoto’s Thyroiditis. Selenium supplementation decreases the level of anti-TPO antibodies. The supplementation of Selenium increases the level of T4 levels.MethodsThe mean and standard deviation (SD) of all 8 studies was were calculated. One of the researches had all the information in figures, and only the levels of anti-TPO antibodies and FT4 were obtained. Heterogenicity was estimated using I2.ResultsThe p-value calculated for Anti-TPO by SPSS of the eight groups had a p-value of 0.142. The p-value calculated for T4 levels by SPSS of the five groups had a p-value of 0.239. The heterogenicity test was zero after the I2 test. The studies that were included in the systematic review were assessed by Prisma diagram and selected among the articles resulted from search keywords selenium and anti tpo and hashimotho thyroiditis on different data sources. All the participants were evaluated by sex, ages, duration of the study and the levels of anti tpo ab and thyroxin (t4) and then using SPSS software to deploy metanalysis in the systematic review.Conclusionin 6 of 8 studies it was a relation of selenium and thyroid status, whereas 2 studies were not. As We ran meta analysis on the data we realized that there is not significant desired effect from selenium on thyroid antibodies against previous metanalysis done by other researchers.

Download Full-text

No difference between Hashimoto's thyroiditis and Graves' disease in the association of other autoimmune conditions - systematic review and meta-analysis

Authorea ◽

10.22541/au.158316311.15138335 ◽

2020 ◽

Author(s):

Greta Pham Dobor ◽

Lilla Hanak ◽

Peter Hegyi ◽

Katalin Marta ◽

Andrea Parniczky ◽

...

Keyword(s):

Systematic Review ◽

Hashimoto’S Thyroiditis ◽

Meta Analysis ◽

Hashimoto's Thyroiditis ◽

Graves Disease ◽

Autoimmune Conditions

Download Full-text

Prevalence and predictor for malignancy of contralateral thyroid nodules in patients with unilateral PTMC: a systematic review and meta-analysis

Endocrine Connections ◽

10.1530/ec-21-0164 ◽

2021 ◽

Author(s):

Weidi Wang ◽

Ling-Jun Kong ◽

Hong-Kun Guo ◽

Xiang-Jin Chen

Keyword(s):

Hashimoto’S Thyroiditis ◽

Thyroid Nodules ◽

Meta Analysis ◽

Lesion Size ◽

Cochrane Library ◽

Categorical Variables ◽

Hashimoto's Thyroiditis ◽

Capsular Invasion ◽

Thyroid Microcarcinoma ◽

Increased Risk

Background: The presence of clinically negative nodules on the contralateral lobe is common in patients with unilateral papillary thyroid microcarcinoma (PTMC). The appropriate operational strategies of contralateral thyroid nodules remain controversial. In this study, we analyzed clinical features that could be predictors for malignancy of contralateral thyroid nodules coexisting with diagnosed unilateral PTMC. Methods: The literatures published from January 2000 to December 2019 were searched in PubMed, Cochrane Library, Embase, Web of Science, CNKI, and Wan Fang database. Odds ratio (OR) with 95% confidence intervals (CI) were used to describe categorical variables. Heterogeneity among studies was examined by the Q test and I2 test; potential publication bias was detected by Harbord test and ‘trim and fill’ method. Results: 2541 studies were searched and 8 studies were finally included in this meta-analysis. The results showed that the rate of carcinoma in contralateral nodules was 23% (OR=0.23, 95%CI=0.18-0.29). The pooled data indicated that contralateral malignancy was not associated with age, gender, primary lesion size, ipsilateral central lymph node metastasis and multifocality of contralateral lesion. The following variables have correlations with an increased risk of contralateral malignancy: multifocality of primary carcinomas (OR=3.93, 95%CI=2.70-5.73, p<0.0001), capsular invasion (OR=1.61, 95%CI=1.10-2.36, p=0.01), and Hashimoto's thyroiditis (OR=1.57，95%CI=1.13-2.20, P=0.008). Conclusions: Based on our meta-analysis, the rate at which contralateral malignancy are preoperatively misdiagnosed as benign is 23%. The risk factors for contralateral malignancy in unilateral PTMC patients with contralateral clinical negative nodules include multifocality of primary carcinomas, capsular invasion, and Hashimoto's thyroiditis.

Download Full-text

Correction to: Effect of selenium supplementation on antioxidant markers: a systematic review and meta-analysis of randomized controlled trials

HORMONES ◽

10.1007/s42000-020-00224-8 ◽

2020 ◽

Vol 19 (3) ◽

pp. 451-451

Author(s):

Motahareh Hasani ◽

Shirin Djalalinia ◽

Maryam Khazdooz ◽

Hamid Asayesh ◽

Maryam Zarei ◽

...

Keyword(s):

Systematic Review ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Selenium Supplementation ◽

Controlled Trials ◽

Randomized Controlled ◽

Antioxidant Markers

Download Full-text

Effects of Selenium Supplementation on Graves’ Disease: A Systematic Review and Meta-Analysis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2018/3763565 ◽

2018 ◽

Vol 2018 ◽

pp. 1-10 ◽

Cited By ~ 4

Author(s):

Huijuan Zheng ◽

Junping Wei ◽

Liansheng Wang ◽

Qiuhong Wang ◽

Jing Zhao ◽

...

Keyword(s):

Systematic Review ◽

Thyroid Function ◽

Meta Analysis ◽

Selenium Supplementation ◽

Control Group ◽

Graves Disease ◽

Cochrane Central Register ◽

Placebo Administration ◽

Increased Risk ◽

Tsh Levels

Low selenium status is associated with increased risk of Graves’ disease (GD). While several trials have discussed the efficacy of selenium supplementation for thyroid function, in GD patients, the effectiveness of selenium intake as adjuvant therapy remains unclear. In this systematic review and meta-analysis, we aimed to determine the efficacy of selenium supplementation on thyroid function in GD patients. Two reviewers searched PubMed, Web of Science, the Cochrane Central Register of Controlled Trials, and four Chinese databases for studies published up to October 31, 2017. RCTs comparing the effect of selenium supplementation on thyroid hyperfunction in GD patients on antithyroid medication to placebo were included. Serum free thyroxine (FT4), free triiodothyronine (FT3), thyrotrophic hormone receptor antibody (TRAb), and thyroid-stimulating hormone (TSH) levels were assessed. Ten trials involving 796 patients were included. Random-effects meta-analyses in weighted mean difference (WMD) were performed for 3, 6, and 9 months of supplementation and compared to placebo administration. Selenium supplementation significantly decreased FT4 (WMD=-0.86 [confidence interval (CI)-1.20 to -0.53]; p=0.756; I2=0.0%) and FT3 (WMD=-0.34 [CI-0.66 to -0.02]; p=0.719; I2=0.0%) levels at 3 months, compared to placebo administration; these findings were consistent at 6 but not 9 months. TSH levels were more elevated in the group of patients taking selenium than in the control group at 3 and 6, but not 9 months. TRAb levels decreased at 6 but not 9 months. At 6 months, patients on selenium supplementation were more likely than controls to show improved thyroid function; however, the effect disappeared at 9 months. Whether these effects correlate with clinically relevant measures remains to be demonstrated.

Download Full-text